HAL (France)
open access
Molecular engineering of lysosome-based degraders unveils a rapidly expanding therapeutic strategy
The targeted degradation of oncogenic or misfolded proteins has emerged as a promising therapeutic strategy. While proteolysis-targeting chimeras (PROTACs) and related technologies have successfully hijacked the ubiquitin-proteasome system to eliminate disease-driving proteins, recent advances highl
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ProMeta: Few-shot PROTAC-targeted degradation prediction across E3 ligases#996704
- Identification of dual-targeting PROTACs for ataxia telangiectasia and RAD3-related and aurora kinase A as chemo-sensitizers for leukemia cells#1066337
- PROTACs: The Future of Leukemia Therapeutics#730890
- MERIT, a cellular system coordinating lysosomal repair, removal and replacement#1298626
- Nouvelle classe d'anticorps thérapeutiques ciblant la destruction des antigènes dans les lysosomes#308209
Record · ID 1235560
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive